Načítá se...
Anti‐FIRΔexon2 autoantibody as a novel indicator for better overall survival in gastric cancer
There is no clinically available biomarker for efficiently indicating the overall survival or therapy response of gastric cancer (GC). The autoantibodies (Abs) in the sera of anti‐far‐upstream element‐binding protein‐interacting repressor‐lacking exon2 (FIRΔexon2), anti‐sorting nexin 15, and anti‐sp...
Uloženo v:
| Vydáno v: | Cancer Sci |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7894018/ https://ncbi.nlm.nih.gov/pubmed/33306856 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14767 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|